Antileukemic Activity of Sechium Hybrid H387 Extract Associated with SIRT1 Downregulation and p53 Acetylation in Human Chronic Myeloid Leukemia Cells
Molecules · 2026
DOI: 10.3390/molecules31172998 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2026. Verfasst von Itzen Aguiñiga-Sánchez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hematopoiesis and Leukemia Laboratory, Research Unit on Cell Differentiation and Cancer, Faculty of High Studies Zaragoza, National Autonomous Univer…. Hauptthemen laut MEDLINE: Sirtuin 1, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Tumor Suppressor Protein p53, Plant Extracts. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Autonomous University of Mexico, General Directorate of Academic Personnel Affairs, General Directorate of Academic Personnel Affairs, National Autonomous University of Mexico.
Abstract (Originalsprache)
Chronic myeloid leukemia (CML) is driven by constitutive BCR–ABL1 activity and remains clinically challenging due to disease persistence and resistance to tyrosine kinase inhibitors (TKIs). SIRT1, a NAD+-dependent deacetylase, has been implicated in leukemic cell survival and chemoresistance through negative regulation of p53. In this study, we evaluated the antileukemic effects of the Sechium hybrid H387 extract and its impact on the SIRT1–p53 signaling axis in K562 CML cells. Cell proliferation was assessed using a crystal violet assay, while gene and protein expression were analyzed by RT-qPCR, immunofluorescence, and flow cytometry. Apoptosis was determined by Annexin V/7-AAD staining. The extract significantly inhibited K562 cell proliferation and downregulated SIRT1 expression, reducing its nuclear localization. These effects were associated with increased p53 acetylation at lysine 382 (Ac-K382-p53) and enhanced apoptosis. Notably, a higher percentage of apoptotic cells was observed following extract treatment than with imatinib under the experimental conditions used, although the two agents have distinct mechanisms of action. These findings suggest that the antileukemic activity of Sechium hybrid H387 extract is associated with modulation of the SIRT1–p53 axis and induction of apoptosis in K562 cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematopoiesis and Leukemia Laboratory, Research Unit on Cell Differentiation and Cancer, Faculty of High Studies Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.
- Department of Biomedical Sciences, School of Medicine, Faculty of High Studies Zaragoza, National Autonomous University of Mexico, Mexico City 56410, Mexico.
- Research Department, Bioplenum Biotechnology Institute, Puerto Vallarta 48313, Mexico.
- Postgraduate College, Campus San Luis Potosí, Salinas de Hidalgo 78622, Mexico.
- Research Unit on Gerontology, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.
ORCID-Profile: Itzen Aguiñiga-Sánchez, Daniel Romero-Trejo, Karen Miranda-Duarte, Ernesto Romero-López, Jorge Cadena-Iñiguez, Juana Rosado-Pérez, Víctor Manuel Mendoza-Núñez, Víctor Manuel Macías Zaragoza, Benny Weiss-Steider, Edelmiro Santiago-Osorio
Förderung
- National Autonomous University of Mexico
- General Directorate of Academic Personnel Affairs
- General Directorate of Academic Personnel Affairs, National Autonomous University of Mexico
Zitieren
APA
Aguiñiga-Sánchez, I., Romero-Trejo, D., Miranda-Duarte, K., Romero-López, E., Cadena-Iñiguez, J., Shira, L., Rosado-Pérez, J., Mendoza-Núñez, V. M., Macías Zaragoza, V. M., Weiss-Steider, B., & Santiago-Osorio, E. (2026). Antileukemic Activity of Sechium Hybrid H387 Extract Associated with SIRT1 Downregulation and p53 Acetylation in Human Chronic Myeloid Leukemia Cells. Molecules. https://doi.org/10.3390/molecules31172998
Vancouver
Aguiñiga-Sánchez I, Romero-Trejo D, Miranda-Duarte K, Romero-López E, Cadena-Iñiguez J, Shira L, et al. Antileukemic Activity of Sechium Hybrid H387 Extract Associated with SIRT1 Downregulation and p53 Acetylation in Human Chronic Myeloid Leukemia Cells. Molecules. 2026. doi:10.3390/molecules31172998
BibTeX
@article{AguiigaSnchez2026,
author = {Aguiñiga-Sánchez, Itzen and Romero-Trejo, Daniel and Miranda-Duarte, Karen and Romero-López, Ernesto and Cadena-Iñiguez, Jorge and Shira, Lorena and Rosado-Pérez, Juana and Mendoza-Núñez, Víctor Manuel and Macías Zaragoza, Víctor Manuel and Weiss-Steider, Benny and Santiago-Osorio, Edelmiro},
title = {Antileukemic Activity of Sechium Hybrid H387 Extract Associated with SIRT1 Downregulation and p53 Acetylation in Human Chronic Myeloid Leukemia Cells},
journal = {Molecules},
year = {2026},
doi = {10.3390/molecules31172998}
}
EUVIMED